High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

Ludovini, V. ; Bellezza, G. ; Pistola, L. ; Bianconi, F. ; Di Carlo, L. ; Sidoni, A. ; Semeraro, A. ; Del Sordo, R. ; Tofanetti, F.R. ; Mameli, M.G. ; Daddi, G. ; Cavaliere, A. ; Tonato, M. ; Crinò, L.

Oxford: Elsevier Ltd

Texto completo disponível

Risk factors for relapse after conservative treatment in T1–T2 breast cancer with one to three positive axillary nodes: results of an observational study

Aristei, C. ; Leonardi, C. ; Stracci, F. ; Palumbo, I. ; Luini, A. ; Viale, G. ; Cristallini, E.G. ; Cavaliere, A. ; Orecchia, R.

Oxford: Elsevier Ltd

Texto completo disponível

1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations

Milella, M. ; Orsi, G. ; Palloni, A. ; Salvatore, L. ; Procaccio, L. ; Noventa, S. ; Bozzarelli, S. ; Garajova, I. ; Vasile, E. ; Giordano, G. ; Macchini, M. ; Cavaliere, A. ; Gaule, M. ; Lonardi, S. ; Di Marco, M.C. ; Tortora, G. ; Sperduti, I. ; Reni, M.

Texto completo disponível

697P - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

Merz, V. ; Zecchetto, C. ; Santoro, R. ; Simionato, F. ; Piro, G. ; Sabbadini, F. ; Cavaliere, A. ; Casalino, S. ; Auriemma, A. ; Melisi, D.

Elsevier Ltd

Texto completo disponível

Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

Merz, V. ; Zecchetto, C. ; Santoro, R. ; Simionato, F. ; Piro, G. ; Sabbadini, F. ; Cavaliere, A. ; Casalino, S. ; Auriemma, A. ; Melisi, D.

Texto completo disponível

1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy

Merler, S. ; Zuliani, S. ; Zampiva, I. ; Tregnago, D. ; Casali, M. ; Cavaliere, A. ; Fumagalli, A. ; Riva, S.T. ; Rossi, A. ; Zacchi, F. ; Zaninotto, E. ; Auriemma, A. ; Pavarana, M. ; Soldà, C. ; Benini, L. ; Borghesani, M. ; Lo Cascio, G. ; Tacconelli, E. ; Pilotto, S. ; Milella, M.

Elsevier Ltd

Texto completo disponível

697PPlasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

Merz, V ; Zecchetto, C ; Santoro, R ; Simionato, F ; Piro, G ; Sabbadini, F ; Cavaliere, A ; Casalino, S ; Auriemma, A ; Melisi, D

Oxford University Press

Texto completo disponível

The role of chemotherapy in the landscape of liposarcoma

De Vita, A. ; Recine, F. ; Mercatali, L. ; Miserocchi, G. ; Liverani, C. ; Spadazzi, C. ; Casadei, R. ; Cavaliere, D. ; Bongiovanni, A. ; Pieri, F. ; Medri, L. ; Riva, N. ; Fausti, V. ; Ibrahim, T.

England: Elsevier Ltd

Texto completo disponível

84P Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theranostics in rare neuroendocrine neoplasms

Calabrese, C. ; Miserocchi, G. ; Vanni, S. ; Spadazzi, C. ; De Vita, A. ; Cocchi, C. ; Bongiovanni, A. ; Ranallo, N. ; Pieri, F. ; Frassineti, G.L. ; Tebaldi, M. ; Foca, F. ; Ercolani, G. ; Cavaliere, D. ; Pacilio, C.A. ; Mercatali, L. ; Liverani, C.

Elsevier Ltd

Texto completo disponível

CabaCy-evaluating Cabazitaxel efficaCy by patterns of treatment and disease in metastatic castration resistant prostate cancer (mCRPC) patients: a 5 years, "Real Life", mono-institutional experience

Rossetti, S ; Cavaliere, C ; Romano, F J ; Di Napoli, M ; Cecere, S C ; Iovane, G ; Porricelli, M A ; Pignata, S ; Facchini, G

England

Texto completo disponível